Ana Garrido-Castro
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ana Garrido-Castro as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:24 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06533826 · TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdAna C Garrido-Castro, MD · recruiting · Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer · principal investigator
- Ph1NCT05774886 · Implantable Microdevice for TNBC - Pilot StudyDana-Farber Cancer Institute · withdrawn · Triple Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III · principal investigator
- Ph2NCT04448886 · Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBCAna C Garrido-Castro, MD · active not recruiting · Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:24 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.Breast Cancer Res · 2020111 citationsRCR 4.9
- 19 citationsRCR 9.5
- Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer.J Immunother Cancer · 202517 citationsRCR 3.3